Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERCC1 | P07992 | 1/20 | 0.46 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 7/20 | 0.41 |
| ▸ | CA1 | P00915 | 6/20 | 0.41 |
| ▸ | KDM6B | O15054 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.40 |
| ▸ | RECQL | P46063 | 2/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | FYN | P06241 | 1/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL300287 | 1.00 | ERCC1 (0.46) | ERCC1ERCC4CA2CA1KDM6B | |
| Hydrochloric Acid SCHEMBL15266596 | 0.98 | ERCC1 (0.45) | ERCC1ERCC4CA2CA1KDM6B | |
| SCHEMBL2283372 | 0.85 | GAA (0.42) | ERCC1ERCC4CA2CA1KDM6B | |
| SCHEMBL4159980 | 0.82 | TSHR (0.49) | CA2CA1CA12CA9CA14 | |
| SCHEMBL4159978 | 0.82 | TSHR (0.49) | CA2CA1CA12CA9CA14 | |
| SCHEMBL29051409 | 0.81 | PPARG (0.50) | ERCC1ERCC4CA2CA1NPSR1 | |
| SCHEMBL30467554 | 0.81 | PPARG (0.50) | ERCC1ERCC4CA2CA1NPSR1 | |
| SCHEMBL18144294 | 0.80 | CA2 (0.44) | CA2CA1CA12CA9CA14 | |
| SCHEMBL1794244 | 0.80 | CA2 (0.44) | CA2CA1CA12CA9CA14 | |
| SCHEMBL31540140 | 0.80 | CA2 (0.47) | ERCC1ERCC4CA2CA1KDM6B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117305198-A | Recombinant bacterium and application thereof in synthesis of L-3, 4-dihydroxyphenylalanine | 杭州唯铂莱生物科技有限公司 | 2023-12-29 | — | — | CN | claimed |
| EP-0920307-A2 | DERIVATES FROM BISARYLTETRACARBONACID, AND PHARMARCEUTICAL PRODUCT CONTAINING THEM | Roche Diagnostics GmbH (DE) | 1999-06-09 | — | — | EP | claimed |
| WO-1998006386-A2 | DERIVATES FROM BISARYLTETRACARBONACID, AND PHARMARCEUTICAL PRODUCT CONTAINING THEM | ROCHE DIAGNOSTICS GMBH (DE) | 1998-02-19 | — | — | WO | claimed |
| EP-0580409-A2 | Cosmetic composition containing DOPA derivatives | UNILEVER PLC (GB) | 1994-01-26 | — | — | EP | claimed |
| US-4529603-A | Erythro-3,4-dihydroxyphenylserine | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1985-07-16 | — | — | US | claimed |
| US-4497826-A | THREO-3,4-DIHYDROXYPHENYLSERINE, CARBIDOPA AND BENSERAZIDE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1985-02-05 | — | — | US | claimed |
| JP-58052219-A | — | — | None | — | — | JP | disclosed |
| JP-7278073-A | — | — | None | — | — | JP | disclosed |
| JP-7278074-A | — | — | None | — | — | JP | disclosed |
| JP-7278075-A | — | — | None | — | — | JP | disclosed |
| JP-6157251-A | — | — | None | — | — | JP | disclosed |
| US-11904014-B2 | Immunostimulatory compositions | Assistance Publique—Hopitaux de Paris (FR) | 2024-02-20 | — | — | US | disclosed |
| CN-117305198-A | Recombinant bacterium and application thereof in synthesis of L-3, 4-dihydroxyphenylalanine | 杭州唯铂莱生物科技有限公司 | 2023-12-29 | — | — | CN | disclosed |
| JP-H06157251-A | COSMETIC COMPOSITION | UNILEVER NV | 1994-06-03 | — | — | JP | disclosed |
| EP-0580409-A2 | Cosmetic composition containing DOPA derivatives | UNILEVER PLC (GB) | 1994-01-26 | — | — | EP | disclosed |
| EP-0218440-A3 | N-METHYLPHENYLSERINE ALKYL ESTER DERIVATIVES AND USES THEREOF | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1988-01-13 | — | — | EP | disclosed |
| US-4690949-A | ADMINISTERING 3,4-DIHYDROXYPHENYLSERINE | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1987-09-01 | — | — | US | disclosed |
| EP-0218440-A2 | N-Methylphenylserine alkyl ester derivatives and uses thereof | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 1987-04-15 | — | — | EP | disclosed |
| US-4497826-A | THREO-3,4-DIHYDROXYPHENYLSERINE, CARBIDOPA AND BENSERAZIDE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1985-02-05 | — | — | US | disclosed |
| JP-S5852219-A | REMEDY FOR PARKINSON'S DISEASE (PERKINSONISM) | SUMITOMO CHEM CO LTD | 1983-03-28 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11904014-B2 | Immunostimulatory compositions | CD47, CD74, LY96 | ERCC1 621/4885ERCC4 570/4885CA2 2331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.